"Pharmacogenomic Testing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The detection of genetic variability (e.g., PHARMACOGENOMIC VARIANTS) relevant to PHARMACOGENETICS and PRECISION MEDICINE. The purpose of such genetic testing is to help determine the most effective treatment options and their optimum dosages with least potential risks for DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS.
Descriptor ID |
D000071185
|
MeSH Number(s) |
E01.370.225.562.500 E05.200.562.500 E05.393.435.500 N02.421.308.430.500 N02.421.726.233.221.500
|
Concept/Terms |
Pharmacogenomic Testing- Pharmacogenomic Testing
- Pharmacogenomic Testings
- Pharmacogenomic Screening
- Pharmacogenomic Screenings
- Pharmacogenetic Screening
- Pharmacogenetic Screenings
- Pharmacogenetic Testing
- Pharmacogenetic Testings
Pharmacogenomic Analysis- Pharmacogenomic Analysis
- Pharmacogenomic Analyses
- Pharmacogenetic Study
- Pharmacogenetic Studies
- Studies, Pharmacogenetic
- Pharmacogenetic Analysis
- Pharmacogenetic Analyses
- Pharmacogenomic Study
- Pharmacogenomic Studies
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenomic Testing".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenomic Testing".
This graph shows the total number of publications written about "Pharmacogenomic Testing" by people in this website by year, and whether "Pharmacogenomic Testing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 5 | 6 | 11 |
2018 | 6 | 6 | 12 |
2019 | 2 | 2 | 4 |
2020 | 2 | 0 | 2 |
2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pharmacogenomic Testing" by people in Profiles.
-
Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes. Pharmacogenomics. 2021 07; 22(10):603-618.
-
Structural Variability, Expression Profile, and Pharmacogenetic Properties of TMPRSS2 Gene as a Potential Target for COVID-19 Therapy. Genes (Basel). 2020 12 25; 12(1).
-
Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID-19: A Retrospective Multicenter Study in the United States. Clin Transl Sci. 2021 01; 14(1):153-162.
-
Pharmacogenomics of genetic polymorphism within the genes responsible for SARS-CoV-2 susceptibility and the drug-metabolising genes used in treatment. Rev Med Virol. 2021 07; 31(4):e2194.
-
PharmGKB Tutorial for Pharmacogenomics of Drugs Potentially Used in the Context of COVID-19. Clin Pharmacol Ther. 2021 01; 109(1):116-122.
-
Advances in the Pharmacogenomics of Antiplatelet Therapy. Am J Ther. 2020 Sep/Oct; 27(5):e477-e484.
-
ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations. Pharmacogenomics. 2020 07; 21(10):695-703.
-
Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline. Expert Opin Drug Metab Toxicol. 2019 Sep; 15(9):751-765.
-
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2019 08 26; 12(16):1521-1537.
-
Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis. J Eur Acad Dermatol Venereol. 2019 Apr; 33(4):e175-e177.